A5006874570- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Renal and related cancers
- Prostate Cancer Treatment and Research
- Angiogenesis and VEGF in Cancer
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Gastrointestinal Tumor Research and Treatment
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Lymphatic System and Diseases
- Advanced Breast Cancer Therapies
- Microbial metabolism and enzyme function
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- Glioma Diagnosis and Treatment
Etelä-Karjalan sosiaali ja terveyspiiri
2019-2024
University of Helsinki
2014-2023
Helsinki University Hospital
2013-2022
Hospital General Universitario Gregorio Marañón
2022
University of Turku
1995-2019
Åbo Akademi University
2009-2019
Finland University
2011-2019
Azienda Ospedaliero-Universitaria Careggi
2017
Comprehensive Blood & Cancer Center
2016
U-M Rogel Cancer Center
2016
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab everolimus carcinoma who had received previous treatment.
We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women tumors that overexpressed HER2/neu were also assigned to receive concomitant trastuzumab or no such treatment.We randomly 1010 women axillary-node-positive high-risk node-negative cancer three cycles vinorelbine, followed by (in both groups) fluorouracil, epirubicin, and cyclophosphamide. The 232 whose had an amplified gene further not nine weekly infusions. primary end point was recurrence-free...
<h3>Context</h3>Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared placebo.<h3>Objective</h3>To investigate the role administration duration as adjuvant treatment who have a high estimated risk GIST recurrence surgery.<h3>Design, Setting, and Patients</h3>Patients KIT-positive removed at were entered between February 2004 September 2008 to this randomized, open-label...
Docetaxel has not been compared with vinorelbine as adjuvant treatment of early breast cancer. Efficacy and long-term safety a short course trastuzumab administered concomitantly chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive cancer are unknown.One thousand ten women axillary node-positive or high-risk node-negative were randomly assigned to receive three cycles docetaxel vinorelbine, followed in both groups by fluorouracil, epirubicin, cyclophosphamide (FEC)....
Patient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality life (HRQoL) safety factors on their stated preference.Patients metastatic RCC were randomly assigned to 800 mg per day 10 weeks, a 2-week washout, then 50 (4 weeks on, 2 off, 4...
To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify molecular basis response/nonresponse this agent.Nineteen AF were treated (800 mg/d) as part a phase II study. Tumor specimens analyzed for mutations KIT, PDGFRA, PDGFRB, CTNNB1 (beta-catenin). expression total activated PDGFRB assessed using immunohistochemistry immunoblotting techniques. We also measured plasma levels PDGF-AA PDGF-BB normal patient controls.Three 19 (15.7%)...
9520 Background: Signaling via LAG-3 and other T-cell inhibitory receptors (eg, PD-1) can lead to dysfunction tumor immune escape. Simultaneous blockade of + PD-1 may synergistically restore activation enhance antitumor immunity. In a phase 1/2a study, BMS-986016 (IgG4 mAb targeting LAG-3) ± nivo demonstrated tolerability, peripheral activation, preliminary clinical activity (NCT01968109; Lipson E, et al. J Immunother Cancer. 2016;4[s1]:173 [P232]). Here we describe efficacy in pts with MEL...
CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), plus ipilimumab 1 for four doses followed by (NIVO3+IPI1), (NIVO1+IPI3). We report on the expanded NIVO1+IPI3 cohort and extended follow-up NIVO3 NIVO3+IPI1 cohorts.Patients platinum-pretreated mUC were enrolled in this phase I/II multicenter to receive NIVO3, NIVO3+IPI1, until disease...
Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether benefits have persisted, we performed second planned analysis trial.Eligible had macroscopically completely excised, KIT-positive GIST a high risk recurrence, as determined by using modified National Institutes Health...
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on immune system is unknown.MethodsWe evaluated blood samples from 40 immunotherapy-naive or prior immunotherapy-refractory patients with metastatic melanoma treated anti-LAG-3+anti-PD-1 in phase I trial using single-cell RNA and T cell receptor sequencing...
Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell surface expression induced under inflammatory conditions. It has been shown previously to participate in lymphocyte recirculation by mediating the binding of lymphocytes peripheral lymph node vascular cells an L-selectin–independent fashion. We report here that VAP-1 cDNA encodes type II transmembrane 84.6 kD with single domain located at NH2-terminal end molecule and six potential N-glycosylation sites...
Abstract HuR is a ubiquitously expressed mRNA-binding protein. Intracellular localization of predominantly nuclear, but it shuttles between the nucleus and cytoplasm. In cytoplasm can stabilize certain transcripts. Because nucleocytoplasmic translocation necessary for its activity, was hypothesized that cytoplasmic expression in cancer cells could be prognostic marker. To test significance carcinogenesis breast, we have investigated mouse mammary gland tumor model from 133 invasive ductal...
Hypertension (HTN) is a common toxicity of anti-VEGF (vascular endothelial growth factor) antibody treatment. It may be marker VEGF signalling pathway inhibition and therefore represent cancer biomarker in metastatic colorectal (mCRC) patients treated with chemotherapy bevacizumab. A total 101 consecutive mCRC were standard combined bevacizumab at dose 2.5 mg kg−1 per week single centre. The median follow-up time the alive was 64 months. Blood pressure measured before each infusion, HTN...
Certain somatic alterations in breast cancer can define prognosis and response to therapy. This study investigated the frequencies, prognostic effects, predictive effects of known mutations using a randomized, adjuvant, phase III clinical trial dataset. The FinHER was III, randomized adjuvant involving 1010 women. Patients with human epidermal growth factor receptor 2 (HER2)–positive were further 9 weeks trastuzumab or no trastuzumab. Seven hundred five tumors had sufficient DNA for...
Background: Simultaneous blockade of LAG-3 and PD-1 may synergistically restore T-cell activation enhance antitumor immunity. In a phase 1/2a study (NCT01968109), BMS-986016 (anti–LAG-3) + nivolumab (anti–PD-1) showed promising activity in the mel prior IO cohort (Ascierto et al. J Clin Oncol. 2017;35(suppl) [abstr 9520]). Here, we describe updated efficacy safety larger all-comer biomarker-enriched populations. Methods: Pts received 80 mg 240 Q2W. Primary objectives were objective response...
Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment colorectal cancer (CRC). Prospective data on prevalence oxaliplatin induced acute and long-term neuropathy a real-life patient population its effects quality life (QOL) survival limited, scarce CAPOX versus FOLFOX treated, especially subarctic climate.One hundred forty-four CRC patients (all 72 cases matched controls) were analyzed regarding sensory neuropathy,...
Abstract Background Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety, pharmacokinetics preliminary anti-tumour activity of BET inhibitor ODM-207 in patients with selected solid tumours. Methods was an open-label Phase 1 comprised a dose escalation part, evaluation effect food on pharmacokinetics. administered orally once daily. The part initiated titration initial cohort, followed by 3...
Abstract Purpose: The clinical significance of intratumoral or peritumoral lymph vessel density is not known. LYVE-1, a lymphatic endothelium-specific hyaluronan receptor, novel marker that expressed on endothelial cells both normal and neoplastic tissues. Experimental Design: We investigated expression LYVE-1 by immunhistochemistry in 180 unilateral, invasive ductal breast carcinomas assessed the presence vessels within tumor at periphery. Results: A minority (12%) had vessels, whereas were...